Supplemental material
Postgraduate Medicine
Volume 132, 2020 - Issue 4
Clinical focus: Diabetes - Original Research
Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes
, 
, , , , , , , , & show all
Nadine Beetzb Global Clinical Operations, Early Trials, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germanyhttps://orcid.org/0000-0002-1071-7000View further author information
https://orcid.org/0000-0002-1071-7000View further author information, Regina Sennewaldb Global Clinical Operations, Early Trials, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germanyhttps://orcid.org/0000-0002-6499-0942View further author information
https://orcid.org/0000-0002-6499-0942View further author information, Annette Schuler-Metzc Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germanyhttps://orcid.org/0000-0002-0332-7709View further author information
https://orcid.org/0000-0002-0332-7709View further author information, Julia Bertulisc Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germanyhttps://orcid.org/0000-0002-4863-6003View further author information
https://orcid.org/0000-0002-4863-6003View further author information, , , , , Linda Shapiro Manningf Clinical Development & Medical Affairs - Cardiometabolism, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USAhttps://orcid.org/0000-0001-8229-381XView further author information
https://orcid.org/0000-0001-8229-381XView further author information & show all